Filing Flows › Companies › Fennec Pharmaceuticals › Report card
Fennec Pharmaceuticals earnings report card
Every report on file against what analysts and the company itself expected, and what the stock did
Beat rate3 of 4 reports beat the EPS estimate
Fennec Pharmaceuticals (FENC) beat the analysts' EPS estimate in 3 of its last 4 reports (75%). Next report: Nov 12, 2026, analysts expect EPS $0.11.
Beat rate75% of 4
Average surprise—
Next reportNov 12, 2026
Report by report
| Quarter | Reported | EPS est. | EPS reported | Surprise | Revenue reported |
|---|---|---|---|---|---|
| Q2 2026 | Aug 11, 2026 | $0.02 | $0.05 | n/m | $17.9M |
| Q1 2026 | May 14, 2026 | −$0.02 | $0.01 | n/m | $15.1M |
| Q4 2025 | Mar 24, 2026 | $0.04 | −$0.10 | n/m | $13.8M |
| Q3 2025 | Nov 13, 2025 | −$0.03 | −$0.02 | n/m | $12.5M |
Estimates and reported EPS are the Street's adjusted figures. Revenue reported is from the company's filing. No daily prices are on file for these report days, so the stock's moves are not shown.
Charts
The next report: what to expect → Fennec Pharmaceuticals: every quarter →
Read automatically from SEC filings, earnings releases and public estimates; errors are possible. Not investment advice.